Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Agios Pharmaceuticals has a consensus “Hold” rating from 10 brokerages: five buys, four holds and one sell. The average 12-month price target is $40.88, above the reported share price of $30.02.
• Revenue rose to $44.75 million, well above the $26.39 million consensus estimate, driven by its mitapivat products Pyrukynd and Aqvesme. However, the company reported a $1.69-per-share loss, slightly missing estimates, and remains deeply unprofitable.
• The FDA granted priority review to mitapivat for sickle cell disease, with a decision expected by November 1, 2026, potentially expanding Agios’s addressable market. The company also held $964.8 million in cash and marketable securities to support commercialization and research.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $40.8750.

A number of brokerages have recently issued reports on AGIO. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 7th. Truist Financial lowered their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating on the stock in a report on Friday. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Royal Bank Of Canada lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a "sector perform" rating in a research note on Tuesday, July 7th. Finally, Citigroup boosted their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a "buy" rating in a report on Friday.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $30.02 on Monday. The company has a fifty day simple moving average of $34.48 and a 200 day simple moving average of $30.90. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The company has a market cap of $1.79 billion, a P/E ratio of -4.28 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Sell-side analysts predict that Agios Pharmaceuticals will post -6.12 EPS for the current year.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
• Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
• Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
• Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
• Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Bellevue Group AG raised its position in Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company's stock valued at $149,110,000 after buying an additional 124,586 shares during the last quarter. State Street Corp lifted its stake in Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock valued at $84,604,000 after acquiring an additional 845,433 shares in the last quarter. Erste Asset Management GmbH boosted its holdings in Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company's stock worth $76,343,000 after acquiring an additional 40,000 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP grew its stake in shares of Agios Pharmaceuticals by 6.4% in the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company's stock worth $77,330,000 after acquiring an additional 140,000 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source